Credit Suisse Sees Up to a $7 Cut in Target Price to Clovis (CLVS) if Platinum Resistant/Refractory Removed; M&A Thesis Intact
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/24/2024
- S&P 500 ends higher as markets weigh rising yields, upbeat corporate results
- Meta Platforms reports softer Q2 revenue guidance on plans to boost spending on AI
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- Equities mixed as investors eye earnings; yen on intervention watch
- ServiceNow (NOW) stock falls as refreshed subscription outlook trails estimates
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Hasbro (HAS) brand strength sees earnings top expectations
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
Clovis (CLVS): Solid Treatment Choice but Maintenance Use Seems Unlikely - Stifel
October 7, 2016 11:16 AM EDTStifel analyst Thomas Shrader reiterated a Buy rating and $45 price target on Clovis Oncology (NASDAQ: CLVS) following data at ESMO 2016 that probably had only two new numbers: a 25% response rate in Pt-resistant patients and a 0% response rate in Pt-refractory patients.
Shrader commented, "These numbers are slightly lower than the... More
Clovis Oncology (CLVS) Defended at SunTrust
October 7, 2016 10:56 AM EDTIn addition to Piper (noted earlier), SunTrust is out defending Clovis Oncology (NASDAQ: CLVS) saying there nothing significantly new in the data. Shares of CLVS are down 13.7% after trading down nearly 30% earlier.
... MoreClovis Oncology (CLVS) Bounces Off Lows, Remains Down 13.8%
October 7, 2016 10:44 AM EDTClovis Oncology (NASDAQ: CLVS) is bouncing off earlier lows as analysts at Piper Jaffray defend the name following this morning's data which was sub-par to a competitor's. Shares are up 13.8% after trading down nearly 30% earlier.
... MoreClovis Oncology (CLVS) Announces Presentation of Encouraging Efficacy, Safety Data on Rucaparib in BRCA Ovarian Cancer
October 7, 2016 8:46 AM EDTClovis Oncology (Nasdaq: CLVS) announced the oral presentation of the primary efficacy and safety data from its NDA dataset for rucaparib at the 2016 ESMO Congress in Copenhagen. Rucaparib is currently under priority review with FDA for the monotherapy treatment of advanced ovarian cancer in patients with BRCA-mutated tumors inclusive of both germline and somatic BRCA mutations who have been treated with two or more chemotherapies, and the submission has a PDUFA date of February 23, 2017.
Rucaparib is the Companys oral, small molecule inhibitor of PARP1, PARP2 and PARP3 currently being developed for the... More
